Cytori Therapeutics to Webcast Third Quarter Financial Results on November 15, 2005.SAN DIEGO -- Cytori Therapeutics, Inc. (Frankfurt:XMP (X/Open Management Protocol) A high-level network management protocol governed by X/Open. Network management software written to the XMP interface is shielded from the details of the underlying SNMP or CMIP protocols. ) announced today it will release financial results for the quarter and nine months ended September 30, 2005 on Tuesday, November 15, 2005 at approximately 10:00 a.m. Eastern Standard Time (EST EST electroshock therapy. EST abbr. electroshock therapy ) or 4:00 p.m. Central European Time Central European Time Noun the standard time adopted by Western European countries one hour ahead of Greenwich Mean Time, corresponding to British Summer Time Abbrev: (CET) (CET CET abbr. Central European Time CET Central European Time CET n abbr (= Central European Time) → hora de Europa central CET abbr ). The company's management will host a conference call at 10:30 a.m. (EST) or 4:30 p.m. (CET) to discuss the results. The audio webcast may be accessed under "Events & Webcasts" in the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website at http://www.cytoritx.com. The webcast will be available live and by replay two hours after the call on the company's website and archived for 90 days. A telephone replay will be available for one week. To access the replay, please call +1-303-590-3000 (PIN: 11043499#) or +49 (0) 69 58 99 90 568 (PIN: 133583#). About Cytori Therapeutics Cytori Therapeutics (Frankfurt:XMP) is discovering and developing proprietary, cell-based therapeutics utilizing adult stem cells derived from adipose adipose /ad·i·pose/ (ad´i-pos) 1. fatty. 2. the fat present in the cells of adipose tissue. ad·i·pose adj. Of, relating to, or composed of animal fat; fatty. , also known as fat tissue. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution(TM) system to isolate and concentrate a patient's own stem cells in about an hour. This system will dramatically improve the speed in which personalized, cell-based therapies can be delivered to patients. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion